Genetic background of adrenal cortex tumours – news

Czech version

Authors: A. Kreze jr. ¹; P. Vaňuga ²; M. Pura ²
Authors‘ workplace: II. interní oddělení FN Na Bulovce Praha, přednosta prim. MU Dr. Jiří Koskuba2 Endokrinologické oddelenie Národného endokrinologického a diabetologického ústavu Ľubochňa, Slovenská republika, prednosta prim. MU Dr. Peter Vaňuga, PhD. ¹
Published in: Vnitř Lék 2010; 56(12): 1279-1285
Category: Celebration

Overview

This review has summarized the current knowledge of the genetic background of tumors originating from adrenocortical tissue, manifested as a part of inherited or familial syndromes, as well as specific forms of sporadic tumors caused by aberrant expression of G‑ protein coupled receptors.

Key words:
adrenal gland – tumor – genetics – genes – syndrome

Sources

1. Brandi ML, Gagel RF, Angeli A et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001; 86: 5658– 5671.

2. Koch CA, Pacak K, Chrousos GP. The molecular pathogenesis of hereditary and sporadic adrenocortical and adrenomedullary tumors. J Clin Endocrinol Metab 2002; 87: 5367– 5384.

3. Langer P, Cupisti K, Bartsch DK et al. Adrenal involvement in multiple endocrine neoplasia type 1. World J Surg 2002; 26: 891– 896.

4. Ozawa A, Agarwal SK, Mateo CM et al. The parathyroid/ pituitary variant of multiple endocrine neoplasia type 1 usually has causes other than p27Kip1 mutations. J Clin Endocrinol Metab 2007; 92: 1948– 1951.

5. Pellegata NS, Quintanilla‑ Martinez L,Siggelkow H et al. Germ‑line mutations in p27KiP1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci USA 2006; 103: 15558– 15563.

6. Georgitsi M, Raitila A, Karhu A et al. Germline CDKN1B/ p27Kip1 mutation in multiple endocrine neoplasia. J Clin Endocrinol Metab 2007; 92: 3321– 3325.

7. Agarwal SK, Mateo CM, Marx SJ. Rare germline mutations in cyclin‑dependent kinase inhibitor genes in MEN1 and related states. J Clin Endocrinol Metab 2009; 94: 1826– 1834.

8. Fritz A, Walch A, Piotrowska K et al. Recessive transmission of a multiple endocrine neoplasia syndrome in the rat. Cancer Res 2002; 62: 3048– 3051.

9. Franklin DS, Godfrey VL, O’Brien DA et al. Functional collaboration between different cyclin‑dependent kinase inhibitors suppresses tumor growth with distinct tissue specificity. Mol Cell Biol 2000; 20: 6147– 6158.

10. Falchetti A, Brandi ML. Multiple endocrine neoplasia type I variants and phenocopies: more than a nosological issue? J Clin Endocrinol Metab 2009; 94: 1518– 1520.

11. Carney JA, Gordon H, Carpenter PC et al. The complex of myxomas, spotty pigmentation and endocrine overactivity. Medicine (Baltimore) 1985; 64: 270– 283.

12. Stratakis CA, Kirschner LS, Carney JA. Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. J Clin Endocrinol Metab 2001; 86: 4041– 4046.

13. Lytras A, Tolis G. Reproductive disturbances in multiple neuroendocrine tumor syndromes. Endocr Relat Cancer 2009; 16: 1125– 1138.

14. Marx SJ, Simonds WF. Hereditary hormone excess: genes, molecular pathways, and syndromes. Endocr Rev 2005; 26: 615– 661.

15. Stratakis CA, Boikos SA. Genetics of adrenal tumors associated with Cushing’s syndrome: a new classification for bilateral adrenocortical hyperplasias. Nat Clin Pract Endocrinol Metab 2007; 3: 748– 757.

16. Stratakis CA. New genes and/ or molecular pathways associated with adrenal hyperplasias and related adrenocortical tumors. Mol Cell Endocrinol 2009; 300: 152– 157.

17. Bourdeau I, Lacroix A. Abberant hormone receptors in adrenal Cushing’s syndrome. Curr Opinion Endocrinol Diab 2002; 9: 230– 236.

18. Ye P, Mariniello B, Mantero F et al. G‑ protein‑coupled receptors in aldosterone‑ producing adenomas: a potential cause of hyperaldosteronism. J Endocrinol 2007; 195: 39– 48.

19. Zwermann O, Suttmann Y, Bidlingmaier M et al. Screening for membrane hormone receptor expression in primary aldosteronism. Eur J Endocrinol 2009; 160: 443– 451.

20. Sandrini F, Stratakis C. Clinical and molecular genetics of primary pigmented nodular adrenocortical disease. Arq Bras Endocrinol Metabol 2004; 48: 637– 641.

21. Horvath A, Bossis I, Giatzakis C et al. Large deletions of the PRKAR1A gene in Carney complex. Clin Cancer Res 2008; 14: 388– 395.

22. Sahut‑ Barnola I, de Joussineau C, Val P et al. Cushing’s syndrome and fetal features resurgence in adrenal cortex‑ specific Prkar1a knockout mice. PLoS Genet 2010; 6: e1000980.

23. Libé R, Fratticci A, Coste J et al. Phosphodiesterase 11A (PDE11A) and genetic predisposition to adrenocortical tumors. Clin Cancer Res 2008; 14: 4016– 4024.

24. Sutherland DJ, Ruse JL, Laidlaw JC. Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. Can Med Assoc J 1966; 95: 1109– 1119.

25. Lifton RP, Dluhy RG, Powers M et al. A chimaeric 11 beta‑hydroxylase/ aldosterone synthase gene causes glucocorticoid‑ remediable aldosteronism and human hypertension. Nature 1992; 355: 262– 265.

26. Pizzolo F, Trabetti E, Guarini P et al. Glucocorticoid remediable aldosteronism (GRA) screening in hypertensive patients from a primary care setting. J Hum Hypertens 2005; 19: 325– 327.

27. Geller DS, Zhang JJ, Wisgerhof MV et al. A novel form of human Mendelian hypertension featuring non‑glucocorticoid remediable aldosteronism. J Clin Endocrinol Metab 2008; 93: 3117– 3123.

28. Stowasser M, Gordon RD, Tunny TJ et al. Familial hyperaldosteronism type II: five families with a new variety of primary aldosteronism. Clin Exp Pharmacol Physiol 1992; 19: 319– 322.

29. So A, Duffy DL, Gordon RD et al. Familial hyperaldosteronism type II is linked to the chromosome 7p22 region but also shows predicted heterogeneity. J Hypertens 2005; 23: 1477– 1484.

30. Jeske YW, So A, Kelemen L et al. Examination of chromosome 7p22 candidate genes RBaK, PMS2 and GNA12 in familial hyperaldosteronism type II. Clin Exp Pharmacol Physiol 2008; 35: 380– 385.

31. Goodarzi MO, Dawson DW, Li X et al. Virilization in bilateral macronodular adrenal hyperplasia controlled by luteinizing hormone. J Clin Endocrinol Metab 2003; 88: 73– 77.

32. Christopoulos S, Bourdeau I, Lacroix A.Aberrant expression of hormone receptors in adrenal Cushing’s syndrome. Pituitary 2004; 7: 225– 235.

33. Lacroix A, Ndiaye N, Tremblay J et al. Ectopic and abnormal hormone receptors in adrenal Cushing’s syndrome. Endocr Rev 2001; 22: 75– 110.

34. Lacroix A, Baldacchino V, Bourdeau Iet al. Cushing’s syndrome variants secondary to aberrant hormone receptors. Trends Endocrinol Metab 2004; 15: 375– 382.

35. Mazzuco TL, Chabre O, Feige JJ et al. Aberrant expression of human luteinizing hormone receptor by adrenocortical cells is sufficient to provoke both hyperplasia and Cushing’s syndrome features. J Clin Endocrinol Metab 2006; 91: 196– 203.

36. Assie G, Louiset E, Sturm N et al. Systematic analysis of G protein‑coupled receptor gene expression in adrenocorticotropin‑independent macronodular adrenocortical hyperplasia identifies novel targets for pharmacological control of adrenal Cushing’s syndrome. J Clin Endocrinol Metab 2010; 95: E253– E262.

37. Lefebvre H, Cartier D, Duparc C et al. Characterization of serotonin(4) receptors in adrenocortical aldosterone‑ producing adenomas: in vivo and in vitro studies. J Clin Endocrinol Metab 2002; 87: 1211– 1216.

38. Li S, Huang S, Peng SB. Overexpression of G protein‑coupled receptors in cancer cells: involvement in tumor progression. Int J Oncol 2005; 27: 1329– 1339.

39. Saner‑ Amigh K, Mayhew BA, Mantero Fet al. Elevated expression of luteinizing hormone receptor in aldosterone‑ producing adenomas. J Clin Endocrinol Metab 2006; 91: 1136– 1142.